



Ri
Skagensgade 1
2630 Taastrup
P: +45 43 50 50 50
CVR-nr. 53 37 19 14
W: www.ri.dk

Octarine Bio ApS

Annual report for the period
1 January to 31 December 2020

(2nd Financial year)

Fruebjergvej 3
2100 København Ø
CVR no. 39 85 73 16

Adopted at the annual general meeting on 10
May 2021

Stephan Christgau
chairman



Table of contents

	Page
Statements	
Statement by management on the annual report	1
Independent auditor's report	2
Management's review	
Company details	5
Management's review	6
Financial statements	
Accounting policies	7
Income statement 1 January 2020 - 31 December 2020	12
Balance sheet at 31 December 2020	13
Statement of changes in equity	15
Notes to the annual report	16



Statement by management on the annual report

The Board of Directors and the Executive board have today discussed and approved the annual report of Octarine Bio ApS for the financial year 1 January - 31 December 2020.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2020 and of the results of the company's operations for the financial year 1 January - 31 December 2020.

In our opinion, management's review includes a fair review of the matters dealt with in the management's review.

Management recommends that the annual report should be approved by the company in general meeting.

Copenhagen, 7 May 2021

Executive Board

Nethaji Janeshawari Gallage
CEO

Nicholas Stuart William Milne
director

Board of Directors

Stephan Christgau
Chairman

Alexandre Ouimet-Storrs

Helga Claudia Blomgren-Hansen

Christian Brix Tillegreen

Lene Gerlach



Independent auditor's report

To the management of Octarine Bio ApS

Opinion

We have audited the financial statements of Octarine Bio ApS for the financial year 1 January - 31 December 2020, which comprise a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared under the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2020 and of the results of the company's operations for the financial year 1 January - 31 December 2020 in accordance with the Danish Financial Statements Act.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements, that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



Independent auditor's report

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on management's review

Management is responsible for management's review.

Our opinion on the financial statements does not cover management's review, and we do not express any form of assurance conclusion thereon.



Independent auditor's report

In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.

Copenhagen, 7 May 2021

Ri Statsautoriseret Revisionsaktieselskab
CVR no. 53 37 19 14

Joachim Munch
State Authorized Public Accountant
MNE no. mne42244



Company details

The company

Octarine Bio ApS
Fruebjergvej 3
2100 København Ø

E-mail: info@octarinebio.com

Website: www.octarinebio.com

CVR no.: 39 85 73 16

Reporting period: 1 January - 31 December 2020

Incorporated: 12 September 2018

Domicile: Copenhagen

Board of Directors

Stephan Christgau, chairman
Alexandre Ouimet-Storrs
Helga Claudia Blomgren-Hansen
Christian Brix Tillegreen
Lene Gerlach

Executive Board

Nethaji Janeshawari Gallage
Nicholas Stuart William Milne

Auditors

Ri Statsautoriseret Revisionsaktieselskab
Skagensgade 1
2630 Taastrup



Management's review

Business review

The Company's purpose is to enable pharmaceutical industry to bring innovative psychedelics and cannabinoids therapeutics to patients. Octarine is combining yeast fermentation with enzymatic platform technologies to develop stable and cost-efficient supply of functionally improved cannabinoid and psilocybin derivatives.

Financial review

The company's income statement for the year ended 31 December 2020 shows a loss of DKK 2,372,514, and the balance sheet at 31 December 2020 shows negative equity of DKK 900,219.

Management considers the Company's financial performance in the year satisfactory and in line with the strategic directions.

Capital resources

During 2020 the Company financed its operating activities by a seed financing round through convertible loans from Vækstfonden and business angels including grants from the Innovation Foundation.

The Company's budget for 2021 shows funding needs that exceed the Company's cash and net working capital position as of 31 December 2020. The Company's ability to finance its operating activities in 2021 is ensured by an extended seed financing round from a group of investors including Vækstfonden and business angels plus a grant from The Innovation Foundation. The extended seed round has been completed after end of the financial year with an amount of USD 1.1 million from the investors and a subsequent conversion of outstanding loans to equity. Furthermore The Innovation Foundation has decided to allocate an InnoBooster grant to the Company of DKK 1.1 million

In the event that the Company is not able to secure additional funding, Management is able to reduce operational activities and maintain the Company as going concern until the end of 2020.

Based on this, it is Management's assessment that the Company's Annual Report may be presented under the going concern assumption.

Reference is made to note 1 for further details.

Significant events occurring after the end of the financial year

No events have occurred after the balance sheet date which could significantly affect the company's financial position.



Accounting policies

The annual report of Octarine Bio ApS for 2020 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B and the Accounting Standard on small enterprises, as well as provisions applying to reporting class C entities.

The accounting policies applied are consistent with those of last year.

The annual report for 2020 is presented in DKK

The Company was founded on 12 September 2018, and the comparative figures therefore covers 16 months.

Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.

On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.

Public grants

Grants for research and development costs which are recognised directly in the income statement are recognised as other operating income in step with the costs to which the grants relate being incurred.



Accounting policies

Income statement

Other operating income

Other operating income comprises items of a secondary nature relative to the company's activities, including gains on the sale of intangible assets and items of property, plant and equipment.

Public grants to cover expenses are recognised in the income statement when it is deemed likely that all grant criteria have been met. Grants which must be repaid under certain circumstances are recognised only when they are not expected to be repaid.

Administrative costs

Administrative costs comprise expenses for Management, administrative staff, office expenses, depreciation, etc.

Staff costs

Staff costs include wages and salaries, including compensated absence and pensions, as well as other social security contributions, etc. made to the entity's employees. The item is net of refunds made by public authorities.

Amortisation, depreciation and impairment losses

Amortisation, depreciation and impairment losses comprise the year's amortisation, depreciation and impairment of intangible assets and property, plant and equipment.

Research and development costs

Research costs comprises costs not satisfying the criteria for capitalisation. Research costs comprise salaries, patent costs, consultancy fee and clinical trial costs etc.

Development costs comprise costs relating to development projects that do not qualify for recognition in the balance sheet and amortisation of recognised development projects.

Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts relating to the financial year. Net financials include interest income and expenses, realised and unrealised capital/exchange gains and losses on foreign currency transactions etc.

Tax on profit/loss for the year

The company is subject to the Danish rules on compulsory joint taxation.

On payment of joint taxation contributions, the current Danish income tax is allocated between the jointly taxed entities in proportion to their taxable income. Entities with tax losses receive joint taxation contributions from entities that have been able to use tax losses to reduce their own taxable profits.



Accounting policies

Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit/loss for the year and directly in equity as regards the portion that relates to entries directly in equity.

Tax of the year includes tax credit for costs incurred in connection with research and development activities under the Danish Credit Regime.

Balance sheet

Intangible assets

Patents and licences

Patents and licences are measured at cost less accumulated amortisation and impairment losses. Patents are amortised on a straight-line basis over the remaining patent period, and licences are amortised over the term of the licence, however not more than years.

Gains and losses on the disposal of patents and licences are determined as the difference between the selling price less costs to sell and the carrying amount at the date of disposal. Gains or losses are recognised in the income statement as other operating income or other operating expenses, respectively.

Tangible assets

Items of plant and machinery and fixtures and fittings, tools and equipment are measured at cost less accumulated depreciation and impairment losses.

The depreciable amount is cost less the expected residual value at the end of the useful life.

Cost comprises the purchase price and any costs directly attributable to the acquisition until the date when the asset is available for use. The cost of self-constructed assets comprises direct and indirect costs of materials, components, sub-suppliers and wages.

Straight-line depreciation is provided on the basis of the following estimated useful lives of the assets:

Other fixtures and fittings, tools and equipment	5 years
--	---------

Assets costing less than DKK 14,100 are expensed in the year of acquisition.

Gains or losses from the disposal of property, plant and equipment are recognised in the income statement as other operating income or other operating expenses, respectively.



Accounting policies

Other investments

Deposits are measured at cost.

Impairment of fixed assets

The carrying amount of intangible assets, items of property, plant and equipment and investments in subsidiaries, associates and participating interests is tested annually for impairment, other than what is reflected through normal amortisation and depreciation.

Receivables

Receivables are measured at amortised cost.

Prepayments

Prepayments recognised under 'Current assets' comprises expenses incurred concerning subsequent financial years.

Cash and cash equivalents

Cash and cash equivalents comprise cash.

Income tax and deferred tax

Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account.

Deferred tax is measured according to the liability method in respect of temporary differences between the carrying amount of assets and liabilities and their tax base, calculated on the basis of the planned use of the asset and settlement of the liability, respectively. Deferred tax is measured at net realisable value.

Deferred tax assets, including the tax base of tax losses allowed for carry forward, are measured at the value to which the asset is expected to be realised, either as a set-off against tax on future income or as a set-off against deferred tax liabilities within the same legal tax entity. Any deferred net tax assets are measured at net realisable value.

Liabilities

Financial liabilities are recognised on the raising of the loan at the proceeds received net of transaction costs incurred. On subsequent recognition, the financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest method. Accordingly, the difference between the net proceeds and the nominal value is recognised in the income statement over the term of the loan.



Accounting policies

Other liabilities, which include trade payables, payables to group entities and other payables, are measured at amortised cost, which is usually equivalent to nominal value.

Deferred income

Deferred income recognised under 'Current liabilities' comprises payments received concerning income in subsequent financial years.



Income statement 1 January 2020 - 31 December 2020

	Note	2020 DKK	2019 DKK
Gross profit		916,667	270,000
Research and development costs		-3,513,170	-728,697
Administrative costs		<u>-473,847</u>	<u>-92,731</u>
Profit/loss before financial income and expenses		-3,070,350	-551,428
Financial income		267,042	4,419
Financial costs		<u>-236,815</u>	<u>-2,553</u>
Profit/loss before tax		-3,040,123	-549,562
Tax on profit/loss for the year	3	<u>667,609</u>	<u>120,607</u>
Net profit/loss for the year		<u>-2,372,514</u>	<u>-428,955</u>
Retained earnings		<u>-2,372,514</u>	<u>-428,955</u>
		<u>-2,372,514</u>	<u>-428,955</u>



Balance sheet at 31 December 2020

	Note	2020 DKK	2019 DKK
Assets			
Acquired licenses		<u>1,703,448</u>	<u>0</u>
Intangible assets	4	<u>1,703,448</u>	<u>0</u>
Other fixtures and fittings, tools and equipment		191,427	0
Leasehold improvements		<u>17,724</u>	<u>0</u>
Tangible assets	5	<u>209,151</u>	<u>0</u>
Deposits		<u>59,702</u>	<u>0</u>
Fixed asset investments		<u>59,702</u>	<u>0</u>
Total non-current assets		<u>1,972,301</u>	<u>0</u>
Other receivables		365,323	24,894
Claim for payment of company capital		0	1,000
Corporation tax		<u>788,216</u>	<u>120,607</u>
Receivables		<u>1,153,539</u>	<u>146,501</u>
Cash at bank and in hand		<u>6,205,680</u>	<u>177,865</u>
Total current assets		<u>7,359,219</u>	<u>324,366</u>
Total assets		<u><u>9,331,520</u></u>	<u><u>324,366</u></u>



Balance sheet at 31 December 2020

	Note	2020 DKK	2019 DKK
Equity and liabilities			
Share capital		40,000	1,000
Retained earnings		-940,219	-428,955
Equity		-900,219	-427,955
Convertible and profit-yielding instruments of debt		5,483,750	0
Other payables		0	4,494
Total non-current liabilities	6	5,483,750	4,494
Convertible and profit-yielding instruments of debt	6	4,083,680	503,245
Trade payables		194,510	199,416
Payables to controlling shareholder		0	7,329
Other payables		406,466	37,837
Deferred income		63,333	0
Total current liabilities		4,747,989	747,827
Total liabilities		10,231,739	752,321
Total equity and liabilities		9,331,520	324,366
Uncertainty about the continued operation (going concern)	1		
Staff	2		
Rent and lease liabilities	7		
Contingent liabilities	8		
Mortgages and collateral	9		



Statement of changes in equity

	<u>Share capital</u>	<u>Share premium account</u>	<u>Retained earnings</u>	<u>Total</u>
Equity at 1 January 2020	1,000	0	-428,955	-427,955
Cash capital increase	39,000	1,861,250	0	1,900,250
Net profit/loss for the year	0	0	-2,372,514	-2,372,514
Transfer from share premium account	0	-1,861,250	1,861,250	0
Equity at 31 December 2020	<u>40,000</u>	<u>0</u>	<u>-940,219</u>	<u>-900,219</u>



Notes

1 Uncertainty about the continued operation (going concern)

During 2020 the Company financed its operating activities by a seed financing round through convertible loans from Vækstfonden and business angels including grants from the Innovation Foundation.

The Company's budget for 2021 shows funding needs that exceed the Company's cash and net working capital position as of 31 December 2020. The Company's ability to finance its operating activities in 2021 is ensured by an extended seed financing round from a group of investors including Vækstfonden and business angels plus a grant from The Innovation Foundation. The extended seed round has been completed after end of the financial year with an amount of USD 1.1 million from the investors and a subsequent conversion of outstanding loans to equity. Furthermore The Innovation Foundation has decided to allocate an InnoBooster grant to the Company of DKK 1.1 million.

At December 31, 2020 the company had a cash position of approximately DKK 6.2 million. With the additional funding it is management's assessment, that the company has sufficient funds to meet its operational required for 2021. In the case that the secured funding does not meet the cash requirement, Management is able to reduce operational activities and maintain the company as going concern until end of 2021.



Notes

	2020 DKK	2019 DKK
2 Staff		
Wages and Salaries	2,130,523	174,446
Other social security expenses	8,880	568
Other staff expenses	<u>23,035</u>	<u>900</u>
	<u>2,162,438</u>	<u>175,914</u>
 Wages and Salaries, other social security expenses and other staff expenses are recognised in the following items:		
Research and development expenses	2,102,912	175,914
Administrative expenses	<u>59,526</u>	<u>0</u>
	<u>2,162,438</u>	<u>175,914</u>
 Average number of employees		
	<u>3</u>	<u>1</u>
3 Tax on profit/loss for the year		
Current tax for the year	<u>-667,609</u>	<u>-120,607</u>
	<u>-667,609</u>	<u>-120,607</u>



Notes

4 Intangible assets

	<u>Acquired licenses</u>
Cost at 1 January 2020	0
Additions for the year	<u>1,900,000</u>
Cost at 31 December 2020	<u>1,900,000</u>
Impairment losses and amortisation at 1 January 2020	0
Depreciation for the year	<u>196,552</u>
Impairment losses and amortisation at 31 December 2020	<u>196,552</u>
Carrying amount at 31 December 2020	<u><u>1,703,448</u></u>

5 Tangible assets

	<u>Other fixtures and fittings, tools and equipment</u>	<u>Leasehold improvements</u>
Cost at 1 January 2020	0	0
Additions for the year	<u>194,827</u>	<u>18,495</u>
Cost at 31 December 2020	<u>194,827</u>	<u>18,495</u>
Impairment losses and depreciation at 1 January 2020	0	0
Depreciation for the year	<u>3,400</u>	<u>771</u>
Impairment losses and depreciation at 31 December 2020	<u>3,400</u>	<u>771</u>
Carrying amount at 31 December 2020	<u><u>191,427</u></u>	<u><u>17,724</u></u>



Notes

6 Long term debt

	Debt at 1 January 2020	Debt at 31 December 2020	Instalment next year	Debt outstanding after 5 years
Convertible and profit-yielding instruments of debt	503,245	9,567,430	4,083,680	1,270,000
Other payables	4,494	0	0	0
	<u>507,739</u>	<u>9,567,430</u>	<u>4,083,680</u>	<u>1,270,000</u>

7 Rent and lease liabilities

	2020 DKK	2019 DKK
Operating lease liabilities, 3-month period of interminability	65,000	0
	<u>65,000</u>	<u>0</u>

8 Contingent liabilities

The company has no contingent liabilities.

9 Mortgages and collateral

The company has signed a deed of pledge of intellectual property rights regarding a specific patent application. The principal amounts to USD 225,000.